

Table 1 Participants, dosing regimens and pharmacokinetic sampling plans for studies included in the population pharmacokinetic analysis

Study code	Subjects	Study design	Dosing regimen	No. of subjects ^a	Food status	PK sampling time	No. of PK samples
Phase 1							
CTR20140854 (NCT03462173)	Healthy volunteers	R, DB, PC, SAD	SD, 6A + 2P 30, 100, 200, 400 mg	n = 24	Fasted at least 10 h	Pre-dose and post-dose 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 h	Rich: 432
CTR20150048	Healthy volunteers	R, DB, PC, MAD	QD × 7 Days, 9A + 3P 100, 200 mg	n = 18	Fasted at least 10 h	Day 1 pre-dose and post-dose 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 h; Day 5, 6, 7 pre-dose; Day 7 post-dose 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 and 120 h	Rich: 558
CTR20170932	Healthy volunteers	R, DB, PC	SD, 6A + 2P 600 mg MD, QD × 7 Days, 9A + 3P 400 mg	SD : n = 6 MD : n = 9	Fasted at least 10 h	SD: Same as CTR20140854 MD: Same as CTR20150048	Rich SD: 108 MD: 279
CTR20150123	Healthy volunteers	R, 2 × 2 cross-over	100 mg	n = 14 or 15 ^b	Fasted at least 10 h or high-fat meal	Pre-dose and post-dose 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72 and 96 h	Rich: 464
Phase 1b							
CTR20150549	Patients	R, DB, PC, PL, MAD	QD × 7 Days, 1:1:1:1, Placebo, 30, 100, 200 mg	n = 18	Fasted at least 4 h	Day 1 pre-dose and post-dose 0.75, 2, 3, 4, 5, 8, 12, 24 h; Day 5, 6, 7 pre-dose; Day 7 post-dose 0.75, 2, 3, 4, 5, 8, 12, 24, 36, 48, 72 and 96 h	Rich: 432
Phase 2							
CTR20170624 (NCT03458481)	Patients	R, OL, PL, MD	QD × 12 Weeks, 1:1 100 mg/Sofosbuvir 400 mg, 200 mg/Sofosbuvir 400 mg	Sparse: n = 107 Rich: n = 22	Sparse: Fasted (at least 2 h before or after a meal) Rich: Fasted at least 10 h	Sparse: Week 1, 2, 4, 6, 8, 10, 12 pre-dose Rich: Day 1 and Week 2 or 4 pre-dose and post-dose 1, 2, 3, 4, 6, 8, 10, 12 and 24 h	Sparse: 872 Rich: 426

^a No. of subjects who administered active drug yimetasvir.^b 14 subjects completed the clinical trial under fasted condition, while 15 subjects completed the clinical trial under fed condition (high-fat meal).

R, Randomized; DB, Double blind; PC, Placebo control; PL, Parallel; SAD, Single ascending dose; MAD, Multiple ascending dose; OL, Open label; SD, Single dose; MD, Multiple dose; QD, Once daily; A, Active drug; P, Placebo.

Rich and sparse mean rich and sparse sampling schedule, respectively. Rich sampling entailed serial blood sampling at defined time points, and sparse sampling (single sample) entailed blood collection at all study visits.